|Bid||67.00 x 1000|
|Ask||67.25 x 800|
|Day's Range||66.69 - 71.84|
|52 Week Range||57.24 - 130.50|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||2.10|
|Earnings Date||Apr 29, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 01, 2010|
|1y Target Est||186.00|
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that today’s scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured. The webcast will take place as previously scheduled at 2:35 p.m. ET and is available here. Conference one-on-one investor meetings have been moved to telephone calls, and the new slides Ligand will be using during those meetings have been posted to www.ligand.com.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences.
NEW YORK, Feb. 19, 2020 -- The law firm of Kirby McInerney LLP is investigating whether the following publicly-traded companies have violated federal securities laws and/or.
Ligand (LGND) delivered earnings and revenue surprises of 4.41% and 8.27%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Anyone researching Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) might want to consider the historical volatility...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
Ligand (LGND) delivered earnings and revenue surprises of -24.62% and 7.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
VICTORIA , Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals (LGND). This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities. Under the license, Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.